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Abstract Medication adherence rates strongly depend on
favorable disease outcomes. It is known that medication
adherence rates are lower for topical treatment than for
systemic treatment. However, to date no validated instru-
ment for the assessment of adherence factors in topical
treatment is available. The aim of this study was to develop
a new questionnaire to assess adherence risk factors in
topical treatment. The development of the Topical Therapy
Adherence Questionnaire (TTAQ) and Patient Preference
Questionnaire (PPQ) was based on a systematic literature
review, and qualitative patient focus interviews and expert
focus groups’ input. The psychometric properties and
comprehensibility of the TTAQ and PPQ were assessed in
a feasibility study with 59 psoriasis patients. Our first
preliminary results indicate that the TTAQ and PPQ are
psychometrically sound and reliable measures for the
assessment of factors influencing topical treatment adher-
ence. The questionnaires are currently being further
developed and various parameters (e.g., time point of
assessment) are currently being tested in an exploratory
pilot study with ca. 2,000 psoriasis patients receiving top-
ical treatment in a European clinical trial. The use of the
final versions of TTAQ and PPQ in clinical practice may
facilitate the early identification of specific non-adherence
factors in patients under topical treatment, which could
enable designing and applying adherence-enhancing inter-
ventions according to the patient’s individual needs.
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Introduction
The WHO defines adherence to treatment as ‘‘the extent to
which a person’s behavior—taking medication, following a
diet, and/or executing lifestyle changes—corresponds with
agreed recommendations from a health care provider.’’ [43]
For the past three decades the importance of adherence has
been recognized and proposed as a key factor in achieving
the therapeutic goals of medical care [16]. The phrase of C.
Everett Koop ‘‘Drugs don’t work in patients who don’t take
them’’ [13] highlights the interaction and close relationship
between patient adherence and desired treatment outcome
[14]. A meta-analysis of 63 studies revealed that adherence
reduces the risk for none or poor treatment outcomes by
26 % and increases threefold the probability of a good
treatment outcome [16]. Importantly, poor medication
adherence compromises safety and effectiveness of treat-
ment, leads to increased morbidity and death and to
increased direct and indirect costs for the health-care sys-
tem [13, 15, 30, 35, 38].
According to its 2003 report the WHO considers
adherence rates in developed countries to average only to
about 50 % [43]. Within the last three decades a number of
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studies have reported that as many as 40 % of the patients
fail to adhere to treatment recommendations while the
percentage of non-adherent patients increases to 70 %
when treatment regimens are too complicated and/or
require lifestyle changes and modification of existing
habits (reviewed in [34]). Patients with acute conditions are
reported to be more adherent than the ones with chronic
conditions whose persistence is very low and is markedly
reduced after the first 6 months of treatment [38].
A number of factors have been identified as influencing
long-term medication adherence such as the complexity,
duration and cost of the treatment, condition characteris-
tics (chronicity, severity, complicating factors), immedi-
acy of beneficial or adverse effects, communication and
information flow between the patient and the physician,
socio-economic variables (health literacy, substance use
disorders), concomitant multiple medication, patients’
beliefs on the necessity of the treatment as well as
patients’ previous treatment experiences and expectancies
from and satisfaction with the current treatment [10, 13,
28, 29].
Adherence to topical treatment has been found chal-
lenging since application of topical medications is often
considered and reported by the patients as being more
difficult than simply taking a pill [20]. Therefore, when
assessing topical treatment adherence one has to consider
additional specific aspects such as the cosmetic and
galenic properties (very greasy, desiccating or sticky
vehicles) and the smell of the preparation, the time
required for its application as well as the convenience of
application [4]. It is therefore not surprising that patients
commonly consider topical treatment as unpleasant and
time consuming and are commonly reporting their non-
adherence to the recommended treatment [32]. However,
non-adherence seems to be an even greater problem than
patients would like to admit since electronic monitoring
of patients’ controlled adherence behavior reveals that
patients tend to overstate their use of medication and
hence their adherence in treatment logs [20, 32]. In
general, topical treatment adherence for dermatological
conditions is poor, with primary adherence—prescription
redemption—being only 65 % (for psoriasis patients pri-
mary adherence is 50 %) and secondary adherence—fol-
lowing prescribed treatment—ranging from 50 to 60 %
[4, 20, 45].
In spite of these increased reported topical treatment
non-adherence rates, only a few studies have attempted to
investigate and identify why patients with dermatologic
conditions fail to follow topical medication recommenda-
tions [12].
To date there is no reliable self-reporting tool for
assessing adherence-influencing factors in patients under
topical treatment. The primary goal of this study was to
develop a novel tool termed Topical Therapy Adherence
Questionnaire (TTAQ) which could allow physicians to
identify potential factors for non-adherent behaviors at an
early stage thus enabling the application of adherence-
enhancing interventions according to each patient’s indi-
vidual needs. Additionally, this study aimed at assessing
the psychometric properties, comprehensibility and feasi-
bility of the preliminary version of the TTAQ in a fea-
sibility check with psoriatic patients under topical
treatment.
Methods
A schematic representation of the methodology for the
development, initial feasibility check and future evaluation
of the TTAQ and the Patient Preference Adherence
Questionnaire (PPQ) is illustrated in Fig. 1.
Fig. 1 Development steps of the TTAQ and PPQ questionnaires
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Development of the item pool
In order to ensure the content validity for the newly
developed tool, an extensive literature search in combina-
tion with qualitative interviews with patient and expert
focus groups was performed.
Literature search
A systematic literature search of the Medline database was
conducted in January and February of 2011. The aim was
to identify existing self-reporting tools, i.e., tools used as
patient reported outcomes for the assessment of aspects
known/expected to influence adherence. Tools which
assessed patient treatment satisfaction, quality of life and
general health status were included in the search protocol
as it has been shown that all these areas might influence
treatment adherence [18, 30]. The first search strategy
included occurrences for QoL and treatment satisfaction
including existing questionnaires known to the authors
[((((((((((((Quality of life OR QoL OR Quality of life
measurements OR Quality of life assessment) OR Quality
of Life [Mesh]) OR euroqol eq-5d) OR sf-36) OR treatment
satisfaction questionnaire) OR FLQA) OR DLQI) OR
Skindex) OR PDI) OR psoriasis disability index) OR
patient benefit index) AND ((validation) OR validity) OR
reliability) AND psoriasis)], which provided 83 hits. Fur-
thermore, the second search strategy included occurrences
for adherence/non-adherence in combination with derma-
tology and topical treatment [((((predictor*) OR factor*)
AND ((((complian*) OR non-complian*) OR adheren*)
OR non-adheren*) AND ((((topic* therap*) OR topic*
treatment*) OR dermatol* treatment*) OR dermatol* the-
rap*)], which provided 40 hits. Citation titles, index terms,
and abstracts from both searches were screened to identify
potentially relevant articles containing or describing
already existing tools, which were subsequently retrieved
for full-text review [1–3, 5–9, 11, 12, 17, 19, 21–27, 31, 36,
39–42, 44, 46].
Patient qualitative focus group interviews
In order to include all relevant aspects, needs and views
of psoriasis patients, qualitative focus group interviews
were conducted in February and March 2011, one with a
national [4 (3 men and 1 woman) members of the Ger-
man Patient’s Psoriasis Association—Deutscher Psoriasis
Bund e.V] and an international [6 members (2 from
Germany, 1 each from Spain, Denmark, Sweden, and The
Netherlands) of the European Federation of Psoriasis
Patient Organization—EUROPSO] patient advisory
board. Patients participating in the interviews were
selected according to their experience with topical
treatment and in general with managing psoriasis and not
according to their psoriasis condition. The aim was to
have a representative population as the TTAQ question-
naire could be used for assessing adherence-influencing
factors in all patients under topical treatments. Guided by
an interviewer, participants were asked to give their
feedback on the following topics: ‘‘important character-
istics to be satisfied with topical treatment’’, e.g., efficacy
of treatment, side effects, ‘‘criteria to judge a topical
treatment as practicable’’, e.g., galenic and cosmetic
properties, time expenditure required for application, how
often should the medication be applied, ‘‘important fac-
tors for the appraisal of the value of a topical treatment’’,
e.g., expectations regarding the effect of the treatment,
immediacy of beneficial effects and ‘‘important factors for
being adherent with a prescribed topical treatment’’, e.g.,
information received regarding the treatment and its
correct application, recollection of this information, fre-
quency of visits to the physician.
Expert qualitative focus groups
A total of 11 experts from the fields of dermatology (7),
psychology (1), health economic (1) and clinical research
(2) were invited to participate in an expert panel meeting in
April 2011. The corresponding experts reviewed each item
of the developed item pool, identified via the literature
search and confirmed during the patient interviews, and its
relevance and suitability was evaluated for inclusion or
exclusion from the newly developed TTAQ.
TTAQ feasibility check
The 71-item containing TTAQ was initially assessed in a
feasibility check with n = 59 psoriasis patients who were
selected from different sites and who used topical treat-
ments for psoriasis. The draft version of the questionnaire
was sent to the patients along with a cover letter explaining
them the scope for the development of this questionnaire
and that their feedback is requested in order to perform an
initial feasibility check and importantly to assess the
comprehensibility of the items. Patients were asked to
answer the TTAQ and to comment on the comprehensi-
bility and relevance of the TTAQ items on a separate sheet.
Patients were requested to fill-out the questionnaire anon-
ymously and send it back to the authors per post. Item
characteristics were analyzed descriptively by computing
mean, standard deviation, range, skewness and kurtosis.
Item difficulty and item–total correlation were also calcu-
lated for all items. Reliability of the TTAQ scales was
assessed by computing internal consistencies (Cronbachs’s
a) over all items.




Sixteen assessment tools were identified which were generic,
dermatology specific or psoriasis specific. Out of these tools,
11 were considered as relevant to our research aims: the Eu-
roQOL 5D [8], the Freiburg Life Quality Assessment (FLQA)
[46], the Short Form 36 (SF36) and Short Form 12 (SF12)
[11], the Dermatology Life Quality Index (DLQI) [23], the
Skindex [7], the Treatment Satisfaction Questionnaire for
Medication (TSQM) [2], the Psoriasis Disability Index (PDI)
[11], the Patient Benefit Index (PBI) [6], the Belief and
Behavior Questionnaire (BBQ) [16], the Brief Medication
Questionnaire [33] and the Medication Adherence Self-
Report Inventory (MASRI) [34]. These tools assessed either
adherence-influencing factors or treatment satisfaction in
patients under medication, or disease related or general quality
of life in dermatological diseases or in psoriasis. In summary,
these tools addressed the following areas: psyche, pain,
symptoms, side effects, everyday coping, mobility, self
assessment/health status treatment evaluation, overall satis-
faction/condition, professional- and social life, choice of
clothing, sports/leisure, love-life, satisfaction efficacy medi-
cation, satisfaction symptom relief, satisfaction time required,
special questions regarding side effects, overall satisfaction
medication, valuation/trust in medication, risk–benefit
assessment, benefit assessment of treatment, cost of treatment
and effect of treatment. After a careful examination, consid-
eration and discussion of these constructs, the following
domains were decided by the authors to be included in the
newly developed TTAQ and to be placed under discussion by
the qualitative patient and expert focus interviews: ‘‘Patient’s
benefit from treatment’’, ‘‘Knowledge, communication and
relationship with the physician’’ and ‘‘Patient preference and
satisfaction with the treatment’’. The items within the domains
‘‘Patient’s benefit from treatment’’ and ‘‘Patient preference
and satisfaction with treatment’’ were created with a special
focus on topical treatment while the ones within the domain
‘‘Knowledge, communication and relationship toward the
doctor’’ assess the quality of the patient–physician relation-
ship as well as the amount of information the patients receive
concerning their condition and its treatment with the rela-
tionship to the physician. Subsequently, the draft version of
the TTAQ was created by formulating items within these
domains that aimed at reflecting and assessing topical treat-
ment adherence-influencing factors.
Patient qualitative focus group interviews
The later analysis of all items collected and discussed
during these interviews revealed that all aspects reported
by the patients were already mentioned in the relevant
literature and included in the item pool that had been
created from the literature search.
Expert qualitative focus groups
No relevant changes to the presented items were deemed
necessary.
TTAQ construction
A total of 71 items were decided to be included into the
first version of the TTAQ. The TTAQ included now the
four domains ‘‘Patient’s benefit from treatment’’,
‘‘Knowledge, communication and relationship with the
physician’’, ‘‘Patient preference’’ and ‘‘Patient satisfaction
with treatment’’. All items were scaled in a four-point
Likert format (0 = strongly disagree, 1 = disagree,
2 = agree and 3 = strongly agree), with a supplementary
option to tick ‘‘Does not apply to me’’.
TTAQ feasibility check
Out of 89 patients with psoriasis to whom the TTAQ
questionnaire was sent, 59 (66.3 %) completed and
returned the questionnaire. Sociodemographic and medical
baseline data of the patients were not considered.
Out of the 71 four-point ordinal-scaled items, 6 items
showed a range lower than 3.00. Difficulties, item–total cor-
relations and selection indices for each item are shown in
Suppl. Table 1. Item difficulty should range between D =
0.20 and 0.80 [33]. Two items showed high difficulties
(D \ 0.20), i.e., it was very difficult to reach high values in
these items. 14 items showed very low difficulties (D [ 0.80),
i.e., it was very easy to approach high ratings on these items.
The item–total correlation is defined as the correlation of
responses to individual items with overall test score without
the respective item. The higher the correlation, the more the
item results are consistent with the scale as a whole. An
insufficient item–total correlation is assumed if the item–
total correlation ritt is lower than 0.20 [33]. No item showed
an item–total correlation of ritt \ 0.20. The lowest values
showed the items 13 (ritt = 0.20) and item 14 (ritt = 0.26).
The Mittenecker and Ebel selection criterion (Sj) con-
siders both the item–total correlation and the item difficulty
and hence is regarded as a better evaluation criterion than
the use of the item difficulty and item–total correlation
alone. Items with Sj \ 0.50 are regarded as less suitable
[33]. As seen in Suppl. Table 1, two items (which also
showed the lowest item–total correlation) did not reach this
criteria (13, Sj = 0.24 and 14, Sj = 0.29).
Internal consistency was measured by Cronbach’s a over
all items. All items had Cronbach’s a values that were higher
than 0.80 and hence were considered as acceptable [25].
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Adjustments and modifications
From the item analysis, items 13 and 14 were found to be
the least suitable; both showed the lowest item–total cor-
relations and did not reach the Mittenecker and Ebel
selection criteria. Therefore, both items were omitted from
the final version of the questionnaire. In Table 1 the TTAQ
and the PPQ domains and the ranges of the difficulty, item–
total correlation and selection index are depicted.
On the basis of the patients’ evaluation on item compre-
hensibility and suitability, various expressions and wordings
were adapted in order to reduce misunderstandings of the
items. In addition, items 44–53 referring to the patient pref-
erence domain were decided to form a separate questionnaire
(Patient Preference Questionnaire, PPQ, see Appendix 2),
because a single assessment of the patient’s treatment pref-
erence between current and previous treatment seemed to be
sufficient, while all the other domains included in the TTAQ
should be assessed more than once during the patient’s cur-
rent treatment with a topical medication.
The final version of the TTAQ contained 59 items that
were divided into three domains (see Appendix 1). Table 1
shows for each of the four domains the number of all items
that were included in the final version of the TTAQ and the
PPQ and their range difficulties, item–total correlations and
selection indices.
Discussion
Favorable treatment outcomes are strongly dependent on
medication adherence rates [16]. Importantly, it has been
reported that adherence for patients in daily clinical prac-
tice is significantly different (i.e., lower) than the one
observed in a clinical trial setting and hence not all patients
benefit from a treatment as might be expected from the
results of such clinical trials [18].
Therefore, it is of great importance to have reliable and
easy-to-use tools which can be used in clinical practice for
assessing predictors of treatment adherence and non-
adherence. To date no such a tool exists which is routinely
used in clinical practice for assessing topical treatment
adherence-influencing factors in patients with dermato-
logic conditions. Given that dermatological conditions
significantly impair the patient’s QoL and treatment regi-
mens are often considered as time consuming, complicated
and unpleasant, developing a novel tool that could assess
these specific conditions and patient-related factors seems
to be highly relevant. Additionally, the new tool enables to
assess the relationship and information flow between the
patient and the physician since this is considered to
influence the patient’s treatment adherence to a major
extent.
Those pillars supported the development of the TTAQ.
The first preliminary results of the feasibility check indi-
cate that the TTAQ contains psychometrically sound items
which may be reliable for assessing factors of topical
treatment adherence.
Importantly, both the TTAQ as well as the PPQ were
translated from their German template in a validated way
(forth and back translation) in seven languages: Danish,
Dutch, English, French, Italian, Spanish and Swedish.
Both questionnaires are currently being used in a multi-
center randomized, controlled trial with appr. 2,000 pso-
riasis patients under topical treatment performed in
Denmark, France, Germany, Italy, The Netherlands, Spain,
Sweden and the UK. Within this pilot exploratory study,
both questionnaires will be given to the patients at dif-
ferent time points during their treatment in order to assess
when the questionnaires should be used, i.e., prior to
starting a treatment or after a definite amount of time. In
any case, the final versions of the tools would aim to
identify adherence risk factors early on which would then
enable the physicians to ‘‘predict’’ non-adherent behaviors
from patients as well as the reasons which might lead to
such behaviors. For example, if a patient would reply in
questions 12–17 of the TTAQ that the current topical
treatment limits his/her activities, then this might serve as
a hint for the physician to discuss and address with the
patient these issues and potentially even consider different
treatment possibilities. Furthermore, following the evalu-
ation of the results from the currently ongoing pilot study
the number of items, especially in the TTAQ, will be re-
considered. Since it is aimed that the newly developed
tools will be used—once validated—in daily clinical
practice, any redundant items will be deleted in order to
reduce the time needed to fill-out the questionnaire and
hence to increase its practicability. Summarizing the
ongoing exploratory study mainly aims to further develop
and fine-tune both tools. In accordance with the COSMIN
















7 0.78–0.86 0.58–0.92 0.82–1.26
Satisfaction with
treatment




10 0.63–0.77 0.60–0.97 0.65–1.14
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taxonomy [37] the following validation criteria will be
evaluated either during the currently ongoing exploratory
pilot study or at a later time point: internal consistency,
reliability, content validity, construct validity (including
convergent and discriminant validity, hypotheses testing
and cross-cultural validity), criterion validity, and
responsiveness.
The aim of the future use of TTAQ in clinical practice is
to allow physicians to identify potential factors for non-
adherence at an early time point and to enable them in that
way to apply adherence-enhancing interventions according
to patient’s individual needs.
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0 1 2 3 99
I - Benefit to patients
01 The treatment led to a rapid improvement in my skin 
symptoms.
02 The treatment suppresses flare-ups.
03 I can easily handle my condition with this treatment.
04 With this treatment my skin no longer itches.
05 My skin is no longer painful with this treatment
06 I do not need to get up any earlier than usual because of the treatment.
07 The time expenditure for visits to the physician/clinic is 
acceptable.
08 The time expenditure for the daily therapy is acceptable.
09 I am not late for appointments because of the time spent 
on the treatment.
10 I do not need to change my clothes several times a day because of the treatment.
11 The time required for the treatment does not affect my 
everyday life.
12 The treatment does not limit my leisure activities.
13 The treatment does not limit my sporting activities.
14 The treatment does not limit my professional life.
15 The treatment does not limit my contact with my friends.
Appendix 1
Final English Version of TTAQ






































0 1 2 3 99
16 The treatment does not affect my sex life.
17 The treatment does not limit my general well-being.
18 I am more confident as a result of the treatment.
19 I am enjoying life again as a result of the treatment.
20 As a result of the treatment, I am not worried that my skin 
condition will get worse.
21 All visible skin symptoms have more or less disappeared thanks to the treatment.
22 I consider the improvement in the condition of my skin to be acceptable.
23 The treatment has met my expectations.
24 My personal treatment goals have been met.
25 The side effects of the treatment were acceptable
26 The positive aspects of the treatment outweigh the 
negative ones.
27 The preparation is easy to use.
28 The preparation is also easy to apply in extreme temperatures.
29 The preparation is easy to apply during travel.
30 The preparation is easy to dispense.
31 The tube/bottle is easy to open and close.
32 The tube/bottle is easy to empty.
33 The strength of the bottle/tube makes it suitable for daily 
use.
34 The preparation leaves no residues on my skin.






































0 1 2 3 99
35 The preparation leaves no residues on 
clothing/bedclothes.
36 The preparation is quickly absorbed.
37 The preparation has a nourishing effect.
38 The preparation feels good on my skin.
39 The preparation has a pleasant fragrance.
40 Residues of the preparation are easy to remove from my 
skin.
II – Information, communication and relationship towards the doctor
41 I feel well-informed about my skin condition.
42 My doctor has taken enough time to explain the condition to me.
43 My doctor has given me sufficient information about the treatment.
44 There was sufficient time for me to ask questions.
45 I feel that my health care provider (doctor/medical 
assistant) sympathizes with my situation.
46 I have enough information to be able to carry out the treatment as planned at any time.
47 I have understood how to implement the treatment to 
ensure that I can always easily handle my condition.
III - Satisfaction with the treatment
48 I am satisfied with the speed at which the treatment takes effect.
49 I am satisfied with the continuous “management” I have 
of the condition/flare-ups.
50 I am satisfied with the efficacy of the treatment.
51 I am satisfied with the tolerability of the treatment.






































0 1 2 3 99
01 The current treatment is more effective than the previous topical treatments.
02 The current treatment is easier to use than the previous topical treatments.
03 The current treatment has fewer side effects than the previous topical treatments.
04 I consider the current treatment to be better tolerable than the previous topical treatments.
05 I prefer the current treatment to previous topical treatments.
06 The current treatment is more effective than previous 
systemic treatments.
07 The current treatment is easier to use than previous 
systemic treatments.
08 The current treatment has fewer side effects than previous systemic treatments.
09 I consider the current treatment to be better tolerated than previous systemic treatments.
10 I prefer the current treatment to previous systemic treatments.
Appendix 2





































0 1 2 3 99
52 I am satisfied with the manageability of the preparation.
53 I am satisfied with the preparation's cosmetic properties.
54
I am satisfied with the information my health care 
provider (doctor/medical assistant) has given me on my 
condition.
55
I am satisfied with the information my health care 
provider (doctor/medical assistant) has given me on the 
treatment with the preparation.
56 I am satisfied with the communication with my health 
care provider (doctor/medical assistant).
57 I would recommend the treatment to other patients.
58 I would repeat/continue with the treatment.
59 I have confidence in the treatment.
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